HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00328367

Aripiprazole or placebo added to clozapine for treatment-resistant schizophrenia

About this titleRead the official source — NCT00328367
Medication studyAges 18–65South Korea
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
SeoulSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2005
Recruitment status
Completed
Enrollment listed in the registry
61
Sponsor
Seoul National University Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
South Korea
Age range
From 18 Years to 65 Years
Official registry ID
NCT00328367
Official title
Show the full official title

A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Seoul

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Seoul National University Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including aripiprazole and placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies